Skip to main content
HB

Harmony Biosciences

Harmony Biosciences develops and commercializes therapies for rare neurological disorders, utilizing patient insights to guide its clinical research programs. The company focuses on conditions like narcolepsy, which often go undiagnosed and carry significant stigma, aiming to improve diagnosis and treatment options for affected individuals.

Plymouth Meeting, United StatesFounded 201727910K+ followers
Updated 4 months ago

Funding

$248M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Narcolepsy, a rare neurological disorder, often goes undiagnosed for years, leading to significant stigma and delayed treatment for affected individuals. Current diagnostic and therapeutic options may be insufficient to address the full spectrum of patient needs.

Solution

Harmony Biosciences develops and commercializes therapies specifically for rare neurological disorders, with a strong emphasis on patient-centric drug development. By incorporating patient insights into clinical research programs, the company aims to improve the diagnosis and treatment of conditions like narcolepsy. Harmony Biosciences is committed to delivering medicines to the people who need them most, addressing unmet medical needs in the rare disease space.

Target Audience

The primary target audience includes individuals affected by rare neurological disorders like narcolepsy, as well as the healthcare professionals who diagnose and treat these conditions.

Features

  • Patient-focused drug development model that incorporates patient insights into clinical research programs.
  • Focus on therapies for rare neurological disorders, such as narcolepsy.
  • Commitment to improving diagnosis and treatment options for underserved patient populations.
This profile is AI-generated and may contain inaccuracies.